Introduction
============

Bumetanide is a fast-acting LD, acting on the widely distributed NKCC1 (Slc12a2), and renal-specific NKCC2. LDs act on the loop of Henle and are often used clinically for palliative treatment of renal insufficiency, heart failure, nephrotic syndrome, and hypertension ([@B168]; [@B20]). Patients that were prone to seizures but administered LDs to induce diuresis for these previously mentioned indications, reported notable anti-seizure effects ([@B54]; [@B55]; [@B70]; [@B95]). While various mechanisms for the seizure alleviation were proposed, the use of loop-diuretics as anti-seizure drugs remains under investigation.

In the brain, the Cl^−^ importer NKCC1 is balanced by the function of Cl^−^ extruder, potassium-chloride-cotransporter 2 (KCC2). Increased expression of NKCC1, not balanced with the efflux action of KCC2, has been the rationale behind administration of BTN as an antiseizure agent. BTN has been administered for HIE neonatal seizures ([@B107]; [@B106]), but was reported inefficacious ([@B126]). BTN administered to patients with autism ([@B84]; [@B85], [@B87]), schizophrenia ([@B128]) and TLE ([@B42]), however, reported beneficial effects.

The developmental expression profile of BTN's primary target, NKCC1 ([@B101]; [@B136]), has recently been elucidated. Studies conducted to analyze BTN's BBB penetration ([@B127]), interaction with efflux transporters ([@B37], [@B38]; [@B132]), blood plasma-binding properties ([@B38]), diuresis ([@B8]; [@B95]) and pharmacokinetic (PK) properties ([@B127]) all have addressed questions about BTN's brain availability. Of interest are BTN's possible interactions with NKCC1 in non-neuronal cells ([@B177]).

Maintaining the Transmembrane Cl^−^ Gradient
============================================

Cl^−^ cotransporters, NKCC1 and KCC2, are the primary mediators that maintain neuronal transmembrane Cl^−^ gradient ([@B131]; [@B12]; [@B28]). NKCC1 is expressed in multiple cell types in the CNS, including neurons, contributing to Cl^−^ intracellular accumulation ([@B41]; [@B108]). KCC2 expression, while thought to be neuronal specific ([@B141]; [@B177]), has been found outside the CNS as well ([@B7]), and extrudes Cl^−^ to maintain lower \[Cl^−^\]~i~. These two co-transporters mediate the GABA "switch," and their functions contribute to inhibitory actions of GABA~A~ receptor (GABA~A~R) agonists ([@B118]; [@B80]). Excitation/inhibition imbalance has been attributed to the developmental profiles of NKCC1 and KCC2 protein expression ([@B12]). In the immature brain and in certain pathological states, activation of GABA channels leads to the efflux of Cl^−^ ions due to high \[Cl^−^\]~i~, resulting in membrane depolarization. Achieving a balance between NKCC1 (Cl^−^ influx) and KCC2 (Cl^−^ efflux), by curbing excessive NKCC1 function has been the reasoning behind the off-label use of BTN, both in pre-clinical models and clinical studies (see [Table 1](#T1){ref-type="table"} for details). Despite being a potent NKCC1 antagonist, BTN can also antagonize KCC2 at higher concentrations ([@B35]). The developmental upregulation of KCC2 has been elucidated and confirmed with a wide span of experimental techniques ([@B153]; [@B136]). The expression profile of KCC2 correlates with maturation of different brain regions ([@B165]; [@B28]). The KCC2b isoform is developmentally upregulated, but KCC2a expression remains steady over brain maturation ([@B154], [@B155]; [@B28]). Until recently, however, the developmental profile of NKCC1 isoforms has remained uncertain, mainly due to experimental limitations ([@B101]; [Figure 1](#F1){ref-type="fig"}).

###### 

BTN off-label studies.

                                                                                Study     Model                                                                                                 Strain                                                                                                   Age                                                                                     Sex as a biological variable                               BTN dose                                                               Number of BTN doses                                                                                Dose delivery                                                  Experimental paradigm                                                                                                                                                            Reported effect
  ----------------------------------------------------------------------------- --------- ----------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------- ---------------------------------------------------------- ---------------------------------------------------------------------- -------------------------------------------------------------------------------------------------- -------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------
  **Pre-clinical rodent studies (*in vivo*)**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         
  Neonatal seizures                                                             [@B41]    KA                                                                                                    Long--Evans rats, Wistar rats and C57 mice                                                               (P9--12), (P5--23), and (P7--9), respectively                                           EEG: M (Wistar), sex not specified for Long-Evans or C57   0.1--0.2 mg/kg (*in vivo*); 10 μM *in vitro*                           1 *in vivo* and bath-applied *in vitro*                                                            IP, *in vivo* and bath-applied *in vitro*                      Bath applied post-elevated K+ *(in vitro)* and Injected 15 min post-KA *(in vivo)*                                                                                               Epileptiform activity in hippocampal slices *in vitro*↓; KA-induced seizure's *in vivo* ↓ EEG power
  Neonatal seizures                                                             [@B96]    PTZ                                                                                                   Wistar rats                                                                                              P7, P12, P18                                                                            M                                                          0.2, 0.5, 1, and 2.5 mg/kg                                             1                                                                                                  *In vivo*, IP                                                  Pretreatment 20 min before PTZ *(in vivo)*                                                                                                                                       Dose-dependent effect in P12 (anticonvulsant at 1 mg/kg, and proconvulsant at 2.5 mg/kg); No effect in P7/P18.
  Neonatal seizures                                                             [@B98]    Rapid kindling                                                                                        Wistar rats                                                                                              P11, P14, P21                                                                           M                                                          0.2, 0.5, or 2.5 mg/kg                                                 1.5                                                                                                *In vivo*, IP                                                  Once upon detection of ADT ( + 1/2 dose during kindling procedure                                                                                                                Anticonvulsant at P11, no effect at P14/P21
  Neonatal Sseizures                                                            [@B91]    Right carotid ligation                                                                                Sprague--Dawley rats                                                                                     P7                                                                                      M/F                                                        2.5 and 10 mg/kg                                                       1                                                                                                  *In vivo*, IP                                                  10 min after PB injection, which was administered 15 min post-hypoxia                                                                                                            Anticonvulsant effect together with PB (BTN: 10 mg/kg), no effect with 2.5 mg/kg BTN
  Febrile seizures                                                              [@B78]    Hyperthermia                                                                                          Sprague--Dawley rats                                                                                     P11                                                                                     M                                                          0.1 mg/kg *in vivo*                                                    6                                                                                                  IP, *in vivo* and bath-applied *in vitro*                      Once daily from P11--P17 *in vivo* post-hyperthermia on P11                                                                                                                      Rescue of granule cell ectopia, limbic seizure susceptibility and development of epilepsy
  Neonatal seizures                                                             [@B25]    Hypoxia                                                                                               Long--Evans rats                                                                                         P10                                                                                     M                                                          0.15 or 0.3 mg/kg                                                      1                                                                                                  *In vivo*, IP                                                  15 min prior to seizure induction by hypoxia                                                                                                                                     Reversal of seizure-induced changes in E~GABA~ when compared to PB and/or BTN applied alone
  Neonatal seizures                                                             [@B69]    Right carotid ligation                                                                                CD-1 mice                                                                                                P7, P10                                                                                 M/F                                                        0.1--0.2 mg/kg                                                         1                                                                                                  *In vivo*, IP                                                  1 h post-PB, 2 h post- unilateral carotid ligation                                                                                                                               No effect/seizure aggravation at P10
  Neonatal seizures                                                             [@B162]   Hypoxia                                                                                               Wistar rats                                                                                              P10                                                                                     Not indicated                                              0.5 mg/kg/day                                                          21                                                                                                 *In vivo*, IP                                                  Daily for 3 weeks post-hypoxia                                                                                                                                                   Alteration of newborn DG cell structure and ↓ spontaneous EEG seizure's after HI
  Neonatal seizures                                                             [@B57]    Flurothyl                                                                                             Sprague--Dawley rats                                                                                     Induced seizure's P5--14, tested for developmental alterations from P18--25             M                                                          0.5 mg/kg                                                              10                                                                                                 *In vivo*, IP                                                  Twice daily, once before first flurothyl-induced seizure and again after the last seizure each day                                                                               Normalization of voltage correlation, sociability and seizure threshold
  Neonatal seizures                                                             [@B58]    PTZ after HI (Rice-Vanucci method)                                                                    Sprague--Dawley rats                                                                                     P7                                                                                      Unsexed                                                    0.5 mg/kg                                                              6                                                                                                  *In vivo*, IP                                                  Twice daily for 3 days after surgery                                                                                                                                             PTZ-induced seizure susceptibility ↓, restoration of hippocampal neurogenesis, improved cognitive function
  Neonatal seizures                                                             [@B72]    PTZ                                                                                                   CD-1 mice                                                                                                P7                                                                                      M/F                                                        0.1--0.2 mg/kg                                                         1                                                                                                  *In vivo*, IP                                                  1 h post-PB, 2 h post-PTZ                                                                                                                                                        No effect/seizure aggravation post-PB suppression in P7 females
  TLE                                                                           [@B18]    Pilocarpine                                                                                           Sprague--Dawley rats                                                                                     Adult                                                                                   F                                                          Three dosing protocols: (1) 0.2 mg/kg, (2) 10 mg/kg, (3) 0.8 mg/kg/h   \(1\) Multiple doses first 24 h, then 14, (2) multiple doses first 24 h, then 14, (3) continuous   \(1\) *In vivo*, IP (2) *in vivo*, IP (3) *in vivo*, IV        \(1\) First 24 h all 3--7 h, then twice daily for 2 weeks, (2) first 24 h all 3--7 h, then twice daily for 2 weeks, (3) continuous infusion after bolus of 2 mg/kg/ for 5 days   Combined PB/BTN treatment altered behavior consequences of epileptic rats
  TLE                                                                           [@B138]   KA                                                                                                    C57BL/6 mice                                                                                             Adult                                                                                   M                                                          0.2 mg/kg or 2.0 mg/kg, i.p. *(in vivo)*, and 54.8 μM *(in vitro)*     1 *in vivo* and bath applied *in vitro*                                                            IP, *in vivo* and intrahippocampal administration *in vitro*   BTN 30, 60, 90, and 120 min prior KA administration (*in vivo*) and direct hippocampal injection of BTN 30 min prior to KA injection (*in vitro*)                                ↓ KA-induced ictal activity *in vivo* and SLEs *in vitro*, restoration of diazepam efficacy *in vitro* and *in vivo*
  TLE                                                                           [@B76]    Pilocarpine                                                                                           Wistar rats                                                                                              Adult                                                                                   M                                                          86 ng/day                                                              Continuous                                                                                         *In vivo*, Osmotic minipumps                                   Continuous infusion for 3 days                                                                                                                                                   Restored post-SE NKCC1/KCC2, normalized Cl^−^ homeostasis, ↓ of glutamatergic recurrent mf sprouting in DG
  Autism                                                                        [@B151]   Rats exposed *in utero* to valproate (VPA rats) and mice carrying the Fragile X mutation (FRX mice)   Wistar rats, mice strain not specified                                                                   E18, P0, P2, P4, P7, P8, P15 and P30 (mice); E20, P0, P2, P4, P7, P15, and P30 (rats)   M/F                                                        2--2.5 mg/kg *(in vivo)*, 10 μM *(in vitro)*                           1                                                                                                  In drinking water (*in vivo*) + *in vitro*                     BTN pretreatment -- given to dams in drinking water (*in vivo*) and bath-applied *in vitro*                                                                                      Maternal pretreatment restored electrophysiological and behavioral phenotypes in pups
  Stroke                                                                        [@B171]   Endothelin stroke model                                                                               Wistar rats                                                                                              Adult                                                                                   M                                                          0.2 mg/kg/day                                                          Continuous                                                                                         *In vivo*, IV; mini-osmotic pumps                              21 days - continuous infusion                                                                                                                                                    Enhancement of neurogenesis and behavioral recovery, no effects on inflammation
  Periventricular leukomalacia                                                  [@B62]    Unilateral carotid artery ligation followed by hypoxia                                                Long--Evans rats, protein-enhanced green fluorescent protein transgenic mouse pups (B6/CBA background)   P6                                                                                      M                                                          0.3 mg/kg                                                              6                                                                                                  *In vivo*, IP                                                  Every 12 h for 60 h post-HI                                                                                                                                                      Attenuation of myelin base protein loss and neuronal degeneration 7 days post-HI
  TBI                                                                           [@B93]    Weight drop device                                                                                    Wistar rats                                                                                              Adult                                                                                   M                                                          15 mg/kg                                                               1                                                                                                  *In vivo*, IV                                                  20 min before TBI                                                                                                                                                                ↓ Brain contusion volume
  TBI                                                                           [@B94]    Weight drop device                                                                                    Wistar rats                                                                                              Adult                                                                                   M                                                          15 mg/kg                                                               1                                                                                                  *In vivo*, IV                                                  20 min before TBI                                                                                                                                                                Attenuation of inflammatory response and neuronal loss
  Neuropathic pain                                                              [@B100]   Sciatic nerve injury                                                                                  Sprague--Dawley rats                                                                                     Adult                                                                                   F                                                          30 mg/kg                                                               16                                                                                                 *In vivo*, IP                                                  Days 1--16 - post injury                                                                                                                                                         Prevented spinothalamic tract projecting area changes and hyperalgesia
  Intracerebral hemorrhage                                                      [@B167]   Collagenase                                                                                           Sprague--Dawley rats                                                                                     Adult                                                                                   M                                                          10 and 40 mg/kg                                                        Multiple doses and treatment groups                                                                *In vivo*, oral and IP                                         2 h or 7 days post-ICH, either 6 or 12 h interval orally or IP for 3 days                                                                                                        Minor ↓ in edema after early dosing, no effect on behavior or injury volume, no normalization of ion concentration after late dosing
  **Pre-clinical rodent studies (*in vitro* only)**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   
  Neonatal seizures                                                             [@B40]    Low Mg^2+^                                                                                            Sprague--Dawley rats                                                                                     P4--P7                                                                                  M                                                          10 μM                                                                  Bath-applied                                                                                       *In vitro*                                                     Bath-applied after 5--8 recurrent ictal-like episodes                                                                                                                            Efficacious adjunct to PB, ↓ recurrent tonic-clonic epileptiform activity
  Febrile seizures                                                              [@B130]   Lipopolysaccharide/KA + behavioral febrile seizure                                                    Long--Evans rats                                                                                         P14                                                                                     M                                                          10 μM                                                                  Bath-applied                                                                                       *In vitro*                                                     Bath-applied 30 min after application of 4-AP                                                                                                                                    ↓*In vitro* 4-AP-induced inter-ictal activity in the inflammation and inflammation + FS groups
  TLE                                                                           [@B17]    Pilocarpine                                                                                           Wistar rats                                                                                              Adult                                                                                   M                                                          10 μM                                                                  Bath-applied                                                                                       *In vitro*                                                     Bath-applied; 20 min superfusion 3 weeks post-SE                                                                                                                                 Restoration of IPSP reversal potential and ↓ polysynaptic burst discharge
  Schizophrenia and autism                                                      [@B4]     22q11.2 DS hippocampal neurons                                                                        C57BL/6 J mice                                                                                           Neurons from E18                                                                        Not indicated                                              10 (uM                                                                 Applied to cell culture media                                                                      In vitro                                                       Applied to cell culture media at 16 DIV, then after 16 DIVs ( + baseline spiking activity                                                                                        ( hyperexcitable action of GABA~A~ receptor signaling, restored network homeostatic plasticity in *Lgdel*^+/-^ networks
  **Off-label clinical studies**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      
  Neonatal seizures                                                             [@B65]    Human (case report)                                                                                   n/a                                                                                                      6 weeks                                                                                 F                                                          0.1 mg/kg                                                              1                                                                                                  IV                                                             Single dose, post-PB and fosphenytoin                                                                                                                                            ↓ Mean seizure duration and frequency
  Neonatal seizures                                                             [@B107]   Human                                                                                                 n/a                                                                                                      Gestational age of 37--43 weeks and postnatal age \<48 h                                M/F                                                        0.05, 0.1, 0.2, or 0.3 mg/kg                                           4                                                                                                  IV                                                             Up to four times, 12 h intervals                                                                                                                                                 No anticonvulsant effect, ototoxicity
  Neonatal seizures                                                             [@B106]   Human                                                                                                 n/a                                                                                                      Post-conceptual age of 33--44 weeks                                                     M/F                                                        0.1, 0.2, or 0.3 mg/kg                                                 1                                                                                                  IV                                                             One dose together with PB after establishing PB-resistance with a first-line PB only dose                                                                                        Results and summary statement on clinical [trials.gov](http://trials.gov) awaited
  TLE                                                                           [@B42]    Human                                                                                                 n/a                                                                                                      Adult -- 31, 32, and 37 years                                                           M                                                          2 mg/day                                                               Long-term administration                                                                           Oral                                                           ∼3/4 months + pre-existing anti-epileptic drugs                                                                                                                                  Seizure frequency ↓, epileptiform discharges ↓ on pre-vs. post EEG in 2 out of 3 patients
  Autism                                                                        [@B84]    Human                                                                                                 n/a                                                                                                      Age span from 3 years and 8 months to 11 years and 5 months                             M/F                                                        1 mg/day                                                               Long-term administration                                                                           Oral                                                           0.5 mg twice a day for 3 months                                                                                                                                                  Improvement in IAS with no side effects
  Autism                                                                        [@B85]    Human                                                                                                 n/a                                                                                                      6.8 years ± 13.2 months                                                                 M/F                                                        1 mg/day                                                               Long-term administration                                                                           Oral                                                           0.5 mg twice a day for 3 months, followed by 1 month washout                                                                                                                     Improved CARS, CGI and Autism Diagnostic Observation Schedule values
  Autism                                                                        [@B39]    Human                                                                                                 n/a                                                                                                      2.5--6.5 years                                                                          M/F                                                        1 mg/day                                                               Long-term administration                                                                           Oral                                                           0.5 mg twice a day for 3 months                                                                                                                                                  ABC and CGI scores improved when ABA training combined with BTN treatment, compared to ABA training alone
  Autism                                                                        [@B87]    Human                                                                                                 n/a                                                                                                      2--18 years                                                                             M/F                                                        1.0, 2.0, and 4.0 mg/day                                               Long-term administration                                                                           Oral                                                           0.5, 1.0, and 2.0 mg twice daily for 3 months                                                                                                                                    Improved CARS, SRS and CGI scores
  Autism                                                                        [@B50]    Human                                                                                                 n/a                                                                                                      14.8--28.5 years                                                                        M/F                                                        1 mg/day                                                               Long-term administration                                                                           Oral                                                           Once daily for 10 months                                                                                                                                                         More eye contact, less amygdala activation
  Schizophrenia                                                                 [@B86]    Human (case report)                                                                                   n/a                                                                                                      14 years                                                                                M                                                          2 mg/day                                                               Long-term administration                                                                           Oral                                                           Once daily for 11 months                                                                                                                                                         ↓ Hallucinations
  Schizophrenia                                                                 [@B129]   Human                                                                                                 n/a                                                                                                      55.9 ± 13.9 years                                                                       M/F                                                        1 mg                                                                   Long-term administration                                                                           Oral                                                           Twice daily for 2 months                                                                                                                                                         No effect on PANSS scores/subscores or BPRS score
  Schizophrenia                                                                 [@B128]   Human                                                                                                 n/a                                                                                                      38--67 years                                                                            M/F                                                        1 mg                                                                   Long-term administration                                                                           Oral                                                           Twice daily for 2 months                                                                                                                                                         ↓ Hallucinations
  Parkinson's disease                                                           [@B32]    Human                                                                                                 n/a                                                                                                      ( \>50 years (n ( =4)                                                                   M/F                                                        5 mg                                                                   Long-term administration                                                                           Oral                                                           Once daily for 2 months                                                                                                                                                          Improvement of PD motor symptoms in all four patients, improvement of gait and freezing in 2 of these patients
  **Human *in vitro* studies**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
  Neonatal seizures (tuberous sclerosis complex and focal cortical dysplasia)   [@B145]   Human, TSC cortical slices                                                                            n/a                                                                                                      Infancy through adulthood (1.4--57 years)                                               M/F                                                        10 μM                                                                  Bath-applied                                                                                       *In vitro*                                                     Bath-applied with NBQX and DL-AP5                                                                                                                                                Suppression of PSC amplitude and frequency
  TLE                                                                           [@B121]   Human, surgical resection from hippocampus and temporal neocortex injected into oocytes               n/a                                                                                                      Adult (27, 29, 41, and 43 years)                                                        M/F                                                        12 μM                                                                  Bath-applied                                                                                       *In vitro*                                                     Oocytes treated with BTN (3 h)                                                                                                                                                   Shifted the E~GABA~ to more negative in oocytes injected with membranes from TLE hippocampal subiculum
  Brain tumor related epileptogenesis                                           [@B29]    Human, membranes from peritumoral cortical tissues of epileptic patients injected into oocytes        n/a                                                                                                      Adult (21--67 years)                                                                    M/F                                                        12 μM                                                                  Bath-applied                                                                                       *In vitro*                                                     Oocytes pretreated with BTN (2 h)                                                                                                                                                Abolished difference of depolarized E~GABA~ in oocytes injected with epileptic peritumoral cerebral cortex
  Sturge--Weber Syndrome                                                        [@B150]   Human, neurons from human pediatric SWS cortex *in vitro*                                             n/a                                                                                                      Infancy (6, 9, 13, and 14 months)                                                       M/F                                                        10 μM                                                                  Bath-applied                                                                                       *In vitro*                                                     Bath-applied                                                                                                                                                                     No prominent effects on epileptiform activity
  Focal cortical dysplasia                                                      [@B14]    Human, slices from resected tissue from patients with FCD                                             n/a                                                                                                      2.8--16.9 years; BTN tested in 12 slices from 7 patients                                M/F                                                        8 μM                                                                   Bath-applied                                                                                       *In vitro*                                                     Bath-applied                                                                                                                                                                     Suppressed IIDs in 9 of 12 slices, IIDs reappeared after washout. No effect in 1 case, and reduced frequency and amplitude in 2 cases of FCD Type 1c

NBQX, 2,3-dihydroxy-6-nitro-7-sulfamoyl-benzo\[f\]quinoxaline-2,3-dione; ADT, after discharge threshold; ABA, applied behavior analysis; ABC, autism behavior checklist; BPRS, Brief Psychiatric Rating Scale; BTN, bumetanide; CARS, Childhood Autism Rating Scale; CGI, clinical global impressions; DIV, days in vitro; DG, dentate gyrus; DL-AP5, DL-2-Amino-5-phosphonopentanoic acid; EEG, electroencephalogram; F, female; FCD, focal cortical dysplasia; HI, hypoxia-ischemia; IAS, infantile autistic syndromes; ICH, intracerebral hemorrhage; IIDs, interictal discharges; M, male; mf, mossy fiber; IPSP, inhibitory post-synaptic potential; KA, kainic acid; PD, Parkinson's disease; PTZ, pentylenetetrazole; PB, phenobarbital; PANSS, Positive and Negative Syndrome Scale; PSC, post-synaptic current; sz, seizure; SRS, Social Responsive Scale; SE, status epilepticus; SWS, Sturge--Weber Syndrome; TLE, temporal lobe epilepsy; TBI, traumatic brain injury; TSC, tuberous sclerosis complex; yrs, years.

![Parsing information about NKCC1 isoforms and BTN **(A)** Human vs. rodent NKCC1 expression profiles. mRNA data from microarray probe (hH034657, Illumina Technologies - probe chosen specifically because it spans most of NKCC1) shows developmental upregulation, followed by NKCC1a protein data using western blotting techniques showing a developmental downregulation. Rodent data of NKCC1a protein shows a developmental downregulation, quantitated with western blotting techniques and consistent with human data analyzed with western blotting using the same probes. **(B)** Pharmacological attributes of BTN affecting its direct neuronal modulation; **(B1)** BBB, neuronal and non-neuronal NKCC1, **(B2)** Albumin's high affinity to BTN, **(B3)** BTN's diuretic effects, **(B4)** BTN's short half-life in serum and brain. **(C)** Clinical trials and pre-clinical models with varying results of BTN efficacy, see [Table 1](#T1){ref-type="table"} for further details. Pk, pharmacokinetics; BBB, Blood--Brain Barrier; PD, pharmacodynamics; BM, basement membrane; TJ, tight junction. Panel A data adapted from [@B41] with permission and [@B27] (graphed brain cloud data replotted with R statistical software).](fnins-13-00310-g001){#F1}

Developmental Profile of Nkcc1 Isoform Expression in the Brain
==============================================================

The developmental expression profile of NKCC1 mRNA has been examined in postmortem human brains with RT-PCR and was found to be stable postnatally ([@B101]). This contrasts with the age-dependent reduction of NKCC1 protein expression levels reported with rodent and human western blotting data ([@B41]; [@B69]) ([Figure 1A](#F1){ref-type="fig"}). NKCC1 mRNA has been shown to have predominant expression in ventricular and periventricular cell populations at embryonic and early neonatal ages in the brain ([@B89]). Toward P0, there was no more significant increase in expression of mRNA but distribution within cortical layers changed from ventricular zones to cortical layers ([@B89]). After mRNA splicing, NKCC1 results in two main isoforms, NKCC1a and NKCC1b, that span across many tissue types in humans, including the brain ([@B156]). Commercially available, NKCC1 western blotting antibodies, used in many of the earlier pre-clinical and human studies, failed to detect NKCC1b, one of the two main isoforms of NKCC1 in the brain ([@B41]; [@B101]; [@B69]). The western blotting probes and antibodies targeted exon 21, found in NKCC1a, but not NKCC1b ([@B24]; [@B156]; [@B66]; [@B101]; [@B127]; [@B69]). Since NKCC1b is the predominant isoform expressed in the brain, ([@B156]), the apparent downregulation of NKCC1 total protein in maturing brains could be attributed to this experimental artifact. Additionally, ([@B101]) identified multiple isoforms with different developmental profiles in the human brain. Along with NKCC1a and b, the mRNA expression of recently discovered NKCC1 transcripts, 1--27 (21a), 1--4a and 1--2a were identified and verified in the DLPFC ([@B101]). The mRNA expressions of NKCC1a, NKCC1b, and 1--4a were low during fetal development, increased after birth through adolescence and reached stable levels in adulthood. This is further supported in a study that evaluated NKCC1 mRNA in P5--P90 rats. While high at P5, there was a significant drop at P10 that then remained stable with advancing age. Since P7 in rodents is close to term birth in humans, this would indicate stable NKCC1 mRNA expression in neurons after birth ([@B81]). Transcript 1--2a decreased after birth but was stable throughout postnatal life ([@B101]). Additionally, qRT-PCR was utilized in another study to determine developmental expression of NKCC1 ([@B60]). An upregulation was seen after birth before leveling off at 20 and 23 years of age in the DLPFC and hippocampus, respectfully. Isoform specific quantification was not conducted in this study, however, and probes utilized spanned exons 4--5.

Brain Cloud^TM^ is an open-access online tool^[1](#fn01){ref-type="fn"}^, containing genetic and epigenetic data from human prefrontal cortex postmortem brains ([@B27]). Microarray conducted on human postmortem brain tissue showed NKCC1 mRNA expression profiles from post-conceptual ages through adulthood. These data has been quantitated with two Illumina microarray probes (hHA034657 and hHC001510, Brain Cloud Expression data) spanning the length of all introns and exons to quantitate both isoform transcripts. Both microarray probes show an increase in expression of NKCC1 mRNA as the brain matures (UCSC Genome Browser, Brain Cloud Expression Data). The developmental upregulation of NKCC1 mRNA via microarray mRNA expression data has been reported in many brain regions ([@B136]). In contrast, however, NKCC1 mRNA has been shown to be downregulated in rat neocortical neurons with advancing age (P1--21) when assessed with RT-PCR ([@B172]). Other studies utilized *in situ* hybridization to demonstrate downregulation in visual cortex from P0 to P28 ([@B61]), cerebral cortex and hippocampus \[[@B125] (P0-adult); [@B137] (P1--P28)\]. Different parts of the brain express different levels of NKCC1 at different developmental timepoints. With advancing age, the expressions of certain transcripts are different than of others. With the availability of probes that target different parts of NKCC1 mRNA sequence, it is confounding on how to properly assess isoform-specific developmental NKCC1 profile. To validate their NKCC1 knockout mouse model, one study utilized multiple probes like mouse, rabbit and goat SLC12a2 antibodies against total protein, C-terminus and N-terminus ([@B6]). Revalidation of western blot data with NKCC1-isoform-specific antibodies that can help quantify both NKCC1 isoforms accurately in humans and rodents is needed. Monoclonal antibodies targeting both NKCC1 and NKCC2 are currently available (Developmental Studies Hybridoma Bank at the University of Iowa). While these antibodies cannot help clarify the developmental expression profile of multiple NKCC1 isoform proteins in the brain ([@B101]), their specificity has only been validated using NKCC1-knockout mouse brains ([@B34]). Some studies have tried to tackle this issue by reporting NKCC1 mRNA and comparing it to KCC2 total protein to help evaluate simultaneous expression ([@B130]). No western blotting probe currently allows us to identify and quantitate each isoform of NKCC1 independently. Western blotting samples from different brain regions also contain empty blood vessels lined with ependymal tissue and glial cells, both of which express NKCC1, representing contamination to assertions about neuronal NKCC1 expression profiles. This would be especially true both in embryonic and neonatal developmental brain studies.

Action in Non-Neuronal Cells
============================

NKCC1 has a widespread distribution throughout the body ([@B156]) and maintains cellular ionic homeostasis through electroneutral movement of ions across the membrane ([@B49]; [@B97]). In the CNS, NKCC1 is also expressed in ependymal and glial cells ([@B124]; [@B169]; [@B59]; [@B67]; [@B173],[@B174]; [@B99]; [@B143]; [@B161]; [@B144]). NKCC1, assessed with RNA-seq, shows higher concentration of transcripts in mature astrocytes (human ages 8--63) than fetal astrocytes (18 gestational weeks) ([@B177]). BTN improved ischemic cerebral edema in the post-ischemic brain ([@B174]; [@B114]). This effect is perhaps through BTN's actions on ependymal NKCC1 ([@B123]).

Na-K-Cl co-transport is responsible for regulating K^+^ concentration gradient in astrocytes ([@B53]; [@B159]). This function is especially crucial in attempts to avoid excessive K^+^ accumulation that occurs after astrocyte swelling in pathological conditions, such as ischemia and traumatic brain injury (TBI) ([@B75]; [@B133]; [@B160]). Additionally, NKCC1 is involved in control of extracellular Ca^2+^ ions ([@B88]; [@B5]) and astrocytes regulate neuronal Ca^2+^ levels through Ca^2+^-dependent glutamate release ([@B122]). When NKCC1 activity was ablated or pharmaceutically inhibited in astrocytes, filling of Ca^2+^ endoplasmic-reticulum Ca^2+^ stores in astrocytes was absent following oxygen/glucose deprivation and reoxygenation ([@B88]). Astrocytes are active modulators of neuronal activity. The vital relationship between neurons and astrocytes that allows for proper brain homeostasis could be indicative of further neuronal regulation via astrocytes ([Figure 1B1](#F1){ref-type="fig"}). This concept could underlie one of the multifactorial mechanisms of BTN responsiveness in the CNS due to the role of astrocyte pathologies in the different neurological diseases.

The relationship between aquaporin 4 (AQP4) and NKCC1 has been investigated in the CNS; AQP4 effluxes water in response to NKCC1 transporting water ([@B117]; [@B176]; [@B105]), indicating other possible sites for BTN mediated modulation. NKCC1 expressed in the mouse choroid plexus is the main contributor to cerebrospinal fluid production, through its water-translocating properties ([@B142]). While once thought to be a passive process, recent studies show NKCC1 plays an active role in producing nearly half of the brains daily quota of CSF through the choroid plexus ([@B142]). NKCC1 is also robustly expressed in oligodendrocytes and has a pivotal role in GABAergic functions ([@B125]; [@B161]; [@B5]). Muscimol-induced activation of GABA~A~R's resulted in reduced \[Cl^−^\]~I~, cell shrinkage and NKCC1 activity ([@B161]). In fact, NKCC1 is most robustly expressed in newly formed oligodendrocytes when compared to all other neural cell types including astrocytes, neurons, oligodendrocyte progenitor cells, myelinating oligodendrocytes, microglia and epithelia ([@B177]). BTN increased neurogenesis and alleviated stroke-induced behavioral impairments in adult rats ([@B171]). For the following studies, ([@B112], [@B113]), authors utilized T4 hybridoma pan NKCC1 and NKCC2 antibody. Since endothelial cells in the brain solely express NKCC1 and not NKCC2, one can infer that the quantifications reported were of NKCC1 only. Authors, however, reported it as NKCC protein since probe was not NKCC1 specific. NKCC1 function in endothelial cells, lining CNS microvasculature are significantly controlled by endogenous factors like arginine vasopressin and estradiol, ([@B112], [@B113]). It was previously shown that antagonizing NKCC with BTN reduced edema formation in a rat stroke model ([@B114]). Arginine vasopressin stimulates NKCC activity during ischemia and promotes edema formation ([@B112]). Estradiol was shown to reduce activity of NKCC and decreased edema formation ([@B113]). Therefore, NKCC1 antagonist, BTN, could play a significant role over brain activity even before it crosses the BBB.

Outside the CNS, NKCC1 is expressed in the epithelial cells of the inner ear ([@B36]). Maintenance of homeostasis of inner ear fluids is crucial for proper functioning of the auditory organs, and the inner ear is known to be sensitive to systemic offsets ([@B63]). NKCC1 is expressed in the inner and middle ear ([@B30]; [@B74]; [@B1]). Interestingly, NKCC1-null mice exhibit deafness at birth ([@B36]). NKCC1 suppression can cause both reversible and irreversible hearing loss ([@B164]). Transgenic mice generated to selectively manipulate cochlear NKCC1 resulted in reversible hearing loss in the postnatal mice ([@B164]). Therefore, systemic BTN delivery for CNS disorders during critical developmental periods would also inhibit the cochlear-specific NKCC1 isoform ([@B35]). The ototoxicity reported following BTN interventions in the HIE trial ([@B107]) have been discussed taking the above findings into consideration ([@B126]; [@B3]). Interestingly, a animal model study that utilized mice with mutations of Slc12a2 found that the associated inner ear dysfunction additionally caused motor hyperactivity via increased levels of pCREB and pERK in the nucleus accumbens ([@B6]). These brain circuit effects were independent of loss of NKCC1 in the brain. Acute diuretic effects of BTN could also lead to dyshomeostasis and fluid imbalance in the inner ear, further aggravating ototoxicity, but in a reversible way. NKCC1-null mice exhibit decreased blood pressure ([@B48]), intestinal bleeding ([@B48]), infertility ([@B119]), and salivary secretion reduction ([@B46]; [@B144]). These findings indicate NKCC1 function plays a significant role in multiple organs other than the kidney and brain.

BTN's Brain Availability
========================

Prenatal brains have been thought to be more vulnerable to drugs, toxins and pathological conditions due to an immature BBB ([@B135]). However, the prevalence of efflux transporters present in the placenta may provide protection *in utero*. This protection is lost after birth and may cause the neonatal period to be more vulnerable than the fetal period ([@B135]). However, this understanding has been challenged, especially with regard to neurotoxicology ([@B43]; [@B135]). Trypan blue and other acidic dyes administered systemically have been utilized to investigate the integrity of the BBB ([@B135]). Functionally effective tight junctions are present in the embryonic brain ([@B111]; [@B44]; [@B135]). Therefore, the neonatal BBB is present and functional during development.

The OAT efflux transporter family is responsible for efficacious drug transport ([@B79]; [@B152]; [@B110]). OAT3 mediates the necessary uptake for BTN to reach NKCC in the kidney ([@B21]). Probenecid, while an inhibitor of all members of the OAT family, is a more selective inhibitor of OAT3, and was utilized to study the effects of the PKs of BTN in the brain ([@B37], [@B38]). Probenecid increased the brain levels of BTN ([@B37]; [@B147]). Therefore, activity of OAT3 may contribute significantly to the poor brain access of BTN after systemic administration ([@B92]) ([Figure 1B1](#F1){ref-type="fig"}). Both restricted passive diffusion and active efflux transport by OAT3, murine OAT polypeptide (Oatp1a4), and multidrug resistance protein 4 (MRP4) lowered the concentrations of systemically administered BTN to the brain in *in vivo* experiments ([@B132]). While initially thought that OAT3 is the only transporter that actively effluxes BTN, later studies confirmed that additional transporters may be involved ([@B132]). Excitotoxic insults, however, could result in the failure of the BBB via glutamatergic actions on NMDA receptors expressed on endothelial cells lining the CNS vasculature ([@B170]). This could have potential implications on both the influx and efflux kinetics of BTN in conditions where this is known to occur.

Just as low brain concentrations and rapid CNS efflux of BTN leads to low plasma/brain ratios for BTN; only unbound and non-ionized forms of BTN are able to diffuse across membranes to begin with ([Figure 1B2](#F1){ref-type="fig"}). Based on the calculated pKa of BTN, \>99% is ionized at the plasma pH of 7.4 when assessed with nuclear magnetic resonance (NMR) spectroscopy and ultraviolet visible (UV) spectroscopy ([@B140]), with additional variations if using pooled human blood ([@B158]) or *in vitro* bovine albumin ([@B38]) to test binding. Free and unionized BBB-permeable BTN is much lower after systemic administration, compared to what would be warranted for efficacious brain penetration and NKCC1 antagonization in neurons ([@B127]). Less than 1% of the IP administered BTN (0.15--0.3mg/kg) reached the brain in hypoxic-ischemic insulted P10 rats, showing a similar penetration to those who didn't receive the insult ([@B127]) ([Figure 1B4](#F1){ref-type="fig"}). These results indicate that even ischemic injury to the P10 BBB did not help BTN penetrate the brain at higher concentrations.

Overall, systemic IP injections of BTN yield lower levels of free BTN than IV infusions or injections ([@B116]; [@B18]; [@B127]; [@B162]). Once in plasma, only BTN that is not bound by albumin can enter the brain, skewing the ratio of BTN presence in the brain compared to plasma. Since the concentration of BTN detected in the brain after systemic administration was much lower than what would be needed to antagonize neuronal NKCC1, higher doses of BTN would have to be administered. Doing so, however, would also aggravate all the other systemic or non-neuronal effects of BTN ([@B92]). A short half-life and the presence of efflux transporters further challenges the maintenance of BTN levels in the brain. All of these factors indicate poor CNS interaction of BTN from a therapeutic efficacy standpoint. However, BTN, while only approved as a diuretic, has been reported to show beneficial effects in some neurological disorders. Systemic effects due to non-neuronal action on NKCC1 expressed inside and outside of the BBB needs consideration.

Systemic Effects
================

Low doses of BTN (0.5--2 mg in adults, 0.1--0.3 mg/kg in neonates and children) are sufficient to induce diuresis. With the above concentrations, diuresis is complete in about 4h's ([@B47]). The elimination of BTN is considerably slower in neonatal patients compared with adults ([@B47]), with ranges from 8 to 27 h in neonates and 33--100 min in adults ([@B120]; [@B127]). BTN is also utilized in the treatment of nephrotic syndrome and massive edema (2--6 mg/day) ([@B83]), heart failure (1--3 mg/day) ([@B77]), and liver disease (0.5--4 mg/day) ([@B102]). BTN can be administered orally, intravenously, or intramuscularly and increases urinary output by inhibiting Na^+^ and Cl^−^ in the loop of Henle ([Figure 1B3](#F1){ref-type="fig"}) with secondary actions on the proximal tubules ([@B16]; [@B104]; [@B163]; [@B47]). Side effects of the induced diuresis include volume depletion, electrolyte depletion, and hypokalemia ([@B47]). Repeated doses require caution and should not exceed 10 mg a day ([@B47]).

Off-Label Studies
-----------------

### Neonatal Seizures

The anti-seizure efficacy of BTN by itself or as an adjunct has been evaluated in several pre-clinical models of neonatal seizures ([@B41], [@B40]; [@B25]; [@B69]; [@B72]). BTN alone hyperpolarized the equilibrium potential of Cl^−^ in immature neurons, suppressed epileptiform activity in hippocampal slices *in vitro* and reduced kainic acid induced seizures *in vivo* ([@B41]). BTN seizure suppression data reported in this study resulted in the initiation of clinical trials for BTN for HIE seizures. This was attributed to the hypothesized higher expression of NKCC1 in immature human and rodent brains (see [Figure 1A](#F1){ref-type="fig"} human and animal WB data). However, the developmentally regulated low expression and function of KCC2 at birth may also play a significant role in determining Cl^−^ gradients during early postnatal weeks ([@B131]; [@B80]). Additionally, microarray data show that human NKCC1 mRNA increases into adulthood, and therefore contradicts the developmental hypothesis of high NKCC1 transporter function and its association with early life seizure susceptibility.

*In vitro*, BTN served as an efficacious adjunct to PB to decrease recurrent tonic-clonic epileptiform activity after application of Mg^2+^ free ACSF in the intact immature hippocampus ([@B40]). PB and BTN applied in combination to *ex vivo* hippocampal slices following hypoxia-induced seizures reversed seizure-induced changes in E~GABA~ when compared to PB and/or BTN applied alone ([@B25]). In a *in vivo* model of ischemic seizures, BTN failed as an adjunct to PB in P10 CD-1 mice ([@B69]). The implications in utilizing *in vivo* models boils down to the simplification that many other factors are at play, often times, these attributes are ones that cannot be controlled as in *in vitro* model counterparts. Post-ischemic P7 CD-1 brains were significantly less susceptible to necrotic infarct injury compared to P10 and P12 for the same insult, with no signs of stroke infarcts detected at P7 in the hypoxic-ischemic model ([@B69]). While P10 and P12 CD-1 pups responded to PB, P7 pups did not respond to the same loading dose ([@B69]). PB-inefficacy at P7 was not rescued with co-administration of BTN when administered 1 h post-PB and PB efficacy witnessed in the P10 age group was shunted when BTN was administered, meaning there was significant increase in seizure burden after effective seizure suppression with PB ([@B69]). In a recent model of pentylenetetrazole (PTZ)-induced acute episodic seizures at the same age (P7) and same mouse strain (CD-1), PB effectively suppressed an even higher seizure burden than what was witnessed in the ischemic seizure model where PB was inefficacious ([@B69]; [@B72]). BTN administration 1h post-PB reversed PB efficacy ([@B72]), similar to the ischemic model at P10 ([@B69]). In contrast, BTN significantly reduced PTZ induced seizure susceptibility following hypoxic-ischemic injury at P7 in a rat model ([@B58]). The 3-day BTN treatment also helped restore hippocampal neurogenesis and improved cognitive function in the treated rats ([@B58]). These improvements may suggest the long-term benefits of acute BTN intervention unrelated to the acute modulation of neuronal Cl^−^.

Cl^−^ co-transporter expression levels, following seizure induction, not only differ by type of insults used to induce neonatal seizures in models of pre-clinical research but also by temporal changes from time of the insult ([@B25]; [@B127]; [@B72]). In the CD-1 mouse ischemia model, there was a downregulation of KCC2 total protein, while a PTZ insult in the same strain at the same age resulted in a upregulation of KCC2 ([@B69]; [@B72]). No significant changes were detected in NKCC1 expression in either model, indicating KCC2 may play a critical role in acute post-insult brain plasticity in acquired models of seizures. In the ischemia model of neonatal seizures, it is possible the reported BTN-induced aggravation of PB-suppressed seizures was due to PB-rebound seizures. If BTN aggravated the seizures independently, the mechanism is not understood at this point. Furthermore, it is of interest that BTN aggravated PB-suppressed seizures both in the ischemic and PTZ induced models in a sex-specific manner (see [Table 1](#T1){ref-type="table"}), highlighting the importance of testing sex as a biological variable in every pre-clinical study. [Table 1](#T1){ref-type="table"} highlights the bias toward using only male rodents for pre-clinical studies. In summary, BTN has been reported to have varying efficacies in animal models of neonatal seizures ([@B40]; [@B96]; [@B98]; [@B73]; [@B25]; [@B69]; [@B72]) (see [Figure 1C](#F1){ref-type="fig"} and [Table 1](#T1){ref-type="table"}). These model-specific efficacies of BTN could be explained by multiple factors including but not limited to: (1) post-insult response of Cl^−^ cotransporter expression (both KCC2 and NKCC1), (2) presence of cell-death, edema, albumin leak through disrupted BBB, (3) maturity of the of the BBB ([@B68]) and (4) the role of non-neuronal cells like astrocytes at tight junctions. Developmentally high NKCC1 expression proposed to result in high \[Cl-\]~i~ and thus depolarizing GABA was the hypothesis that formed the basis for the clinical trial for BTN intervention in HIE neonates, but BTN failed as an anti-seizure adjunct to PB ([@B107]; [@B126]).

### Focal Cortical Dysplasia

Focal cortical dysplasia is a malformation of cortical development ([@B64]). The histological characteristics were first described by [@B146]. Three types of cortical dysplasia are recognized ([@B15]), types I, II, and III. Characterization of Type I to Type III FCD is based on the location and extent of histopathological changes associated with cortical dysplasias. In the case of Type III FCD, the dysplasia extends beyond the temporal lobe and is associated with other principal lesions like hippocampal sclerosis or vascular malformations ([@B15]; [@B64]). Dysregulated GABAergic transmissions, either due to disrupted chloride cotransporter function or altered GABA~A~R mediation are some of the reported characteristics of FCD ([@B14]). The effect of BTN was assessed in slices from tissue resected from FCD patients. Bath--applied BTN suppressed interictal discharges, in slices from resected tissue which resumed after washout in physiological artificial CSF ([@B14]). In this study, the effects of BTN were variable. However, it suppressed interictal discharges in 9 of 12 slices (see [Table 1](#T1){ref-type="table"}). The conclusions tied the BTN effects on suppression of the interictal discharges to a hypothesized upregulation of NKCC1, without quantification of NKCC1. The results, however, did report reduced membrane KCC2 expression in ictogenic zones within the resected FCD brain slices.

### Temporal Lobe Epilepsy

Spontaneous rhythmic activity has been reported in brain slices derived from patients with TLE, that were suppressed by glutamatergic or GABAergic signaling antagonists ([@B26]). Brain tissue resected from TLE patients showed alterations in the relative expression of KCC2 and NKCC1 in neurons, which may contribute to epileptiform activity in the subiculum of patients with hippocampal sclerosis ([@B103]). BTN attenuated seizure frequency in two out of three patients with TLE ([@B42]). Seizure models for TLE, including amygdala-kindled rats, pilocarpine-induced SE, post-traumatic seizures, neuronal hyperactivity, ischemia-induced seizures and febrile seizures have been utilized to study altered chloride cotransporter levels ([@B56]; [@B115]; [@B172]; [@B90]; [@B82]; [@B78]; [@B66]; [@B138]). The excitatory GABA caused by NKCC1 upregulation remains the proposed rationale behind testing BTN's efficacy ([@B11]). The contributing role of KCC2 hypofunction in seizure susceptibilities is also being explored ([@B23]). In a recent study, it was shown that local ablation of KCC2 activity in a subset of hippocampal neurons resulted in compromised GABAergic inhibition and development of spontaneous seizures and hippocampal sclerosis ([@B71]).

### Autism

Autism and prevalence of seizures go hand-in-hand ([@B13]). The seizures in patients with autism are often treatment-resistant ([@B134]). High \[Cl^−^\]~i~ makes GABA excitatory, and was proposed to be the basis of the contradictory actions of PB in autistic patients with seizures ([@B85]). Based on these hypotheses, reducing the \[Cl^−^\]~i~ via BTN proved efficacious in an animal model of autism using valproic acid exposure ([@B151]). In a commentary response to this study, however, it was noted that it is premature to consider BTN as a prenatal intervention suitable for ASD due to the lack of proper technical tests and failures to assess the long lasting modifications ([@B9]).

In three separate clinical trials where BTN was administered to patients with autism ranging from infancy to adulthood, BTN significantly improved Childhood Autistic Rating Scale (CARS) scores and attenuated the severity of the disorder overall, with no major side effects other than diuresis ([@B84]; [@B11]; [@B87]). In a recent study, BTN given to a subset of the patients with autism showed the normalization of amygdala activation upon eye contact ([@B50]) ([Figure 1C](#F1){ref-type="fig"}), long-after cessation of the BTN therapy suggesting permanent and corrective alterations to the underlying circuits.

### Schizophrenia

Increased NKCC1 mRNA expression in patients with schizophrenia was also the proposed rationale underlying BTN treatment trials in these patients. Many patients with schizophrenia manifest clinical symptoms that suggest prefrontal cortex dysfunction ([@B166]), and so this region remains of interest to study under pathological conditions. A 7.4-fold upregulation of NKCC1 mRNA was detected in the Brodmann's area 46 in schizophrenia patients ([@B33]). However, more recent data elucidate DLPFC NKCC1b mRNA was significantly decreased in patients with schizophrenia and NKCC1a mRNA remained unchanged when compared to controls ([@B101]). This finding indicates that NKCC1 isoform expression underlying different pathological conditions could differ by the neurological disorder. In both a case study ([@B86]) and a small pilot study ([@B128]), BTN reduced hallucinations in schizophrenic patients. In additional tests, however, where the brief psychiatric rating scale (BPRS) was assessed, BTN treatment had no significant effect when compared to the placebo group ([@B129]).

In schizophrenia and autism, and in the cases where increased NKCC1 expression has been determined, either by western blotting or PCR, it would be of interest to investigate whether the developmental profile of NKCC1 expression is impaired. The potential developmental and functional alterations in NKCC1 isoform expression and distribution both in healthy and diseased brains could help understand the role of NKCC1 in CNS disorders.

Shared Mechanisms With Osmotic Agents
=====================================

Osmotic agents have been administered for treatment of seizures and alleviation of brain injury and edema ([@B31]; [@B95]; [@B157]). Osmotic agents may share mechanism of action(s) with BTN due to their shared diuretic properties. Mannitol (an osmolyte), much like BTN, has been reported to have varying efficacies. The anti-seizure effects of mannitol have long been studied in animal models and humans. In a kainic acid rat model, mannitol (1.5 g/kg, IV, 10 min, 1.5 and 3 h, respectively, after kainic acid administration) yielded a protective effect at 1.5 h after kainic acid seizure induction ([@B10]). Along with anti-seizure effects, mannitol prevented the formations of lesions and other potential neurochemical changes. Additionally, rat CA1 hippocampal slices in solutions made 5--30 mosmol/kg hyperosmotic by additions of mannitol, sucrose, raffinose, [L]{.smallcaps}-glucose and dextran blocked \[K+\]o-induced spontaneous seizures ([@B149]). In contrast, a recent study did not find any anticonvulsant effects of NKCC blockers (LD's) in a electroconvulsive adult seizure model, while other diuretics exhibited some activity at high doses ([@B175]). [@B51] administered a single dose of either 20 mg furosemide (cation-Cl^−^ cotransporter antagonist) or 50 g mannitol to epileptic patients during their surgical procedures for the treatment of intractable epilepsy; both drugs significantly suppressed epileptic-spikes and electrical stimulation-evoked epileptiform discharges in all subjects recorded from electrodes directly placed on the cortical surface. In another study, mannitol was given to pediatric patients experiencing status epilepticus (SE) and raised intracranial pressure. While success rates were not provided in detail, authors concluded that all seizures cannot be treated with one drug. Underlying pathologies must be taken into consideration when choosing what anti-seizure drug to employ, especially in regards to the utilization of diuretics, which have preexisting conflicting success rates ([@B139]). One prominent mechanism shared by diuretics in general, with proposed antiepileptic efficacy is inhibition of carbonic anhydrase. Carbonic anhydrases catalyze reversible hydration/dehydration of CO~2~/HCO~3~^−^, respectively ([@B2]). These actions suppress seizures through disruption of CO~2~ equilibrium with inhibitory action on ion channels ([@B2]). However, carbonic anhydrase inhibition likely is not one of the mechanisms of action of BTN, since BTN is a weak carbonic anhydrase inhibitor (isoforms I, II, III, and XIII) ([@B22]). BTN was inhibitory to carbonic anhydrase for tumor-associated isoforms ([@B22]). Therefore, BTN's mechanism of action via carbonic anhydrase requires further investigations to fully understand its anti-convulsive properties.

Btn Pro-Drugs and Analogs
=========================

To improve BTN accessibility to the brain, pro-drugs with lipophilic and uncharged esters, alcohol and amide analogs have been created. These pro-drugs convert to BTN after gaining access into the brain. There was a significantly higher concentration of ester prodrug, BUM5 (*N*,*N* -- dimethylaminoethyl ester), in mouse brains compared to the parent BTN (10 mg/kg, IV of BTN and equimolar dose of 13 mg/kg, IV of BUM5) ([@B148]). BUM5 stopped seizures in adult animal models where BTN failed to work ([@B148]; [@B45]). BUM5 was also less diuretic and showed better brain access when compared to the other prodrugs, BUM1 (ester prodrug), BUM7 (alcohol prodrug) and BUM10 (amide prodrug). BUM5 was reported to be more effective than BTN in altering seizure thresholds in epileptic animals post-SE and post-kindling ([@B148]). Furthermore, BUM5 (13 mg/kg, IV) was more efficacious than BTN (10 mg/kg, IV) in promoting the anti-seizure effects of PB, in a maximal electroshock seizure model ([@B45]). Compared to BUM5 which was an efficacious adjunct to PB in the above mentioned study, BTN was not efficacious when administered as an adjunct ([@B45]). In addition to seizure thresholds, further studies need to be conducted to assess effects of BUM5 on seizure burdens, ictal events, duration and latencies.

Recently, a benzylamine derivative, bumepamine, has been investigated in pre-clinical models. Since benzylamine derivatives lack the carboxylic group of BTN, it results in lower diuretic activity ([@B109]). This prompted [@B19] to explore the proposed lower diuretic activity, higher lipophilicity and lower ionization rate of bumepamine at physiological pH. Since it is known that rodents metabolize BTN quicker than humans, the study used higher doses of 10 mg/kg of bumepamine similar to their previous BTN studies ([@B116]; [@B18]; [@B148]). Bumepamine, while only being nominally metabolized to BTN, was more effective than BTN to support anticonvulsant effects of PB in rodent models of epilepsy. This GABAergic response, however, was not due to antagonistic actions on NKCC1; suggesting bumepamine may have an off-target effect, which remains unknown. However, the anticonvulsive effects of bumepamine, in spite of its lack of action on NKCC1, are to be noted. Additionally, in another study by the same group, it was shown that azosemide was 4-times more potent an inhibitor of NKCC1 than BTN, opening additional avenues for better BBB penetration and NKCC1-antagonizing compounds for potential neurological drug discovery ([@B52]).

Conclusion
==========

The beneficial effects of BTN reported in cases of autism, schizophrenia and TLE, given its poor-brain bioavailability are intriguing. The mechanisms underlying the effects of BTN, as a neuromodulator for developmental and neuropsychiatric disorders could be multifactorial due to prominent NKCC1 function at neuronal and non-neuronal sites within the CNS. Investigation of the possible off-target and systemic effects of BTN may help further this understanding with the advent of a new generation of brain-accessible BTN analogs.
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